The stock market is not supposed to be entertainment, but for most investors lately things have been downright boring. That will likely continue for a little while longer, says at least one analyst. Paradigm Capital analyst Aazan Habib, in a recent report to clients, said equity indices are following the seasonal script closely right now, […]
Following new data from the company, Raymond James analyst Rahul Sarugaser has raised his price target on Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX). Victoria, BC-based Eupraxia’s lead product is EP-104IAR, is designed to meet what the company says is an unmet medical need to change the way knee pain is […]
Share
Tweet
Share
